针对慢性粒细胞白血病（CML）急变期细胞的特异性异种抗血清。
Specific xenogenous antiserum to cells of chronic myeloid leukemia (CML) in blastic crisis.
作者信息
Baryshnikov A J, Radzikhovskaya R M, Morozova L F, Belyanchikova N I, Slavina E G, Vinogradova J E, Mkheidze D M, Polotskaya T M, Volkova M A, Svet-Moldavsky G J, Nikitin V D, Kutimov V A, Trubitsina V I, Goletsky S A, Glazunov A
出版信息
Biomedicine. 1976 Dec 5;25(9):316-7.
The antiserum was obtained from horses immunized with cells from patients with blastic crisis of CML and completely absorbed with normal white blood cells (WBC). The absorbed antiserum remained cytotoxic to blast cells from nearly half of the patients in blastic crisis and did not react with WBC from patients with Acute Myeloid Leukemia (AML), Acute Lymphoid Leukemia (ALL), Chronic Lymphoid Leukemia (CLL) and Chronic Myeloid Leukemia (CML) in its chronic phase as well as with cells of human normal bone marrow or fetal liver.
该抗血清是从用慢性粒细胞白血病急变期患者的细胞免疫的马中获得的，并用正常白细胞（WBC）完全吸收。吸收后的抗血清对近一半急变期患者的原始细胞仍具有细胞毒性，并且不与急性髓系白血病（AML）、急性淋巴细胞白血病（ALL）、慢性淋巴细胞白血病（CLL）和慢性期慢性粒细胞白血病（CML）患者的白细胞以及人类正常骨髓或胎儿肝脏的细胞发生反应。
Zotero 插件